The frequency of cardiac valvular regurgitation in Parkinson's disease.
To investigate the frequency of cardiac valve regurgitation related with low dose dopamine agonists in patients with Parkinson's disease (PD), echocardiograms were analyzed in 527 consecutive PD patients (448 patients treated with dopamine agonists, 79 patients never treated with dopamine agonists as age-matched controls). The frequency of mild or above mild regurgitation of the aortic valve (AR) was significantly higher in the cabergoline group (13.7%, P < 0.05) compared with the controls (2.5%). Odds ratio adjusted by age and sex for AR was significantly higher in the cabergoline group (OR, 6.45; 95% CI, 1.46-28.60; P = 0.01): odds ratio was significantly higher in patients treated with higher daily doses (OR, 14.41; 95% CI, 3.08-67.38; P = 0.0007) and higher cumulative doses (OR, 15.29; 95% CI, 3.19-73.18; P = 0.0006). No statistical difference was identified in the frequency of the tricuspid and mitral regurgitation. None of the other dopamine agonist groups including pergolide gave higher frequency or higher odds ratio compared with the controls. None of our patients showed severe regurgitation or was operated for valvular heart disease. The question as to whether or not longer duration of low dose dopamine agonist treatment would yield the same results needs further studies.
Yamashiro
Kazuo
K
Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan.
Komine-Kobayashi
Miki
M
Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan.
Hatano
Taku
T
Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan.
Urabe
Takao
T
Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan.
Mochizuki
Hideki
H
Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan.
Hattori
Nobutaka
N
Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan.
Iwama
Yoshitaka
Y
Department of Cardiology, Juntendo University School of Medicine, Tokyo, Japan.
Daida
Hiroyuki
H
Department of Cardiology, Juntendo University School of Medicine, Tokyo, Japan.
Sakai
Michi
M
Department of Health Informatics, Kyoto University School of Public Health, Kyoto, Japan.
Nakayama
Takeo
T
Department of Health Informatics, Kyoto University School of Public Health, Kyoto, Japan.
Mizuno
Yoshikuni
Y
Research Institute for diseases of Old Age, Juntendo University School of Medicine, Tokyo, Japan.
D000368:Aged; D001022:Aortic Valve Insufficiency / Q000139:chemically induced / Q000453:epidemiology; D001381:Azepines / Q000009:adverse effects / Q000627:therapeutic use; D052160:Benzothiazoles / Q000009:adverse effects / Q000627:therapeutic use; D001971:Bromocriptine / Q000009:adverse effects / Q000627:therapeutic use; D000077465:Cabergoline; D018491:Dopamine Agonists / Q000009:adverse effects / Q000627:therapeutic use; D004873:Ergolines / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008944:Mitral Valve Insufficiency / Q000139:chemically induced / Q000453:epidemiology*; D010300:Parkinson Disease / Q000188:drug therapy / Q000453:epidemiology*; D010479:Pergolide / Q000009:adverse effects / Q000627:therapeutic use; D000077487:Pramipexole; D015995:Prevalence
D001381:Azepines; D052160:Benzothiazoles; D018491:Dopamine Agonists; D004873:Ergolines; D010479:Pergolide; D001971:Bromocriptine; C024763:talipexole; D000077487:Pramipexole; D000077465:Cabergoline